Histone Deacetylase Inhibitors Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
Global Histone Deacetylase Inhibitors Market: By Drug Class (Class I, Class II, Class III, Class IV), By Application (Neurology, Oncology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
Global histone deacetylase inhibitors market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024
Market Outline: Global Histone Deacetylase Inhibitors Market
Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers. Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases.
Market Dynamics: Global Histone Deacetylase Inhibitors Market
Rise in prevalence of cancers and neurological disorders drives the global histone deacetylase inhibitors market. Moreover, increase in the R&D activities for the cancer treatment and other diseases, rise in demand to improve effectiveness of newer treatment therapies, and promising pipeline drugs, are anticipated to fuel the global histone deacetylase inhibitors market. However, lack of favorable reimbursement policies and uncertainty issues and stringent regulations for the product approval are restrain the growth of histone deacetylase inhibitors market over the forecast years.
Free sample of this report is available upon request @
Market Scope: Global Histone Deacetylase Inhibitors Market
Histone deacetylase inhibitors market is segmented on the basis of drug class, application, and Distribution Channel
Based on the drug class, the market is segmented into the following:
- Class I
- Class II
- Class III
- Class IV
Based on the application, the market is segmented into the following:
- Neurology
- Oncology
- Others
Based on the distribution channel, the market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Free TOC of this report is available upon request @
Regional Analysis: Global Histone Deacetylase Inhibitors Market
Geographically, global histone deacetylase inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America histone deacetylase inhibitors market is poised to grow at notable CAGR owing to increase in R&D for the development of newer drugs, rise in prevalence of cancer and neurological disorders, and high acceptance of HDAC products are expected to the boost the market. Europe histone deacetylase inhibitors market is rising due to increase in the aging population results to rise in prevalence of neurological disorders, grow in demand for advanced treatments, and pipeline drugs under the various stages of clinical trials are bolster the market. However, Asia Pacific histone deacetylase inhibitors market is poised to grow due to entry of market players into Asia Pacific countries with launch of newer products, rise in medical tourism for cancer treatment in Asia Pacific countries, and large patient pool are expected to offer healthy growth opportunities for the market.
Ask Analyst for Full Information about this report @
Competition Assessment: Global Histone Deacetylase Inhibitors Market
Some of the players in the global histone deacetylase inhibitors market include:
- Novartis AG (Switzerland)
- AstraZeneca Plc (U.K.)
- Pfizer, Inc. (U.S.)
- Celgene Corporation (U.S.)
- Eisai Co. Ltd. (Japan)
- Merck & Co., Inc. (U.S.)
- Acetylon Pharmaceuticals, Inc. (U.S.)
- Celleron Therapeutics Ltd. (U.K.)
- Innovation Pharmaceuticals, Inc. (U.S.)
- Ranedis Pharmaceuticals (U.S.)
Notable Market Developments: Histone Deacetylase Inhibitors Market
- In March 2017, AMO Pharma and Ranedis Pharmaceuticals entered into a collaboration to develop the RND-001, HDAC inhibitor, used in specific lysosomal storage disorders and neurodegenerative disorders
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/histone-deacetylase-inhibitors-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com